ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming all competitor algorithms.
Scailyte™ and ScaiVision™ are registered trademarks proprietary to Scailyte AG.
Recent News
Recent News
Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel
Recent News
Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis
Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today
Recent News
Scailyte Quarterly Update, January 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ScaiVision® performs best-in-class at sample class prediction!
ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a
Recent News
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Recent News
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,
Recent News
Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients
Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel
Recent News
Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis
Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today
Scailyte Quarterly Update, January 2021
Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Recent News
ScaiVision® performs best-in-class at sample class prediction!
ScaiVision® v1.0.0 was released internally and benchmarked in a massive experiment, outperforming a
Scailyte participates @ swissnex san francisco DEMO DAY!
Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day
Recent News
Scailyte Q3 2020 Update
Q3 2020 update on Scailyte's progress towards its mission to save millions of lives.
ETH Industry E-Week 2020 features Scailyte with the headline: Using Artificial Intelligence to unlock the clinical potential of single-cell data.
As ETH- Spin-off Scailyte attends the 2020 Industry eWeek giving updates on the disease area focus,